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489Noncontrast T1 Mapping for the Diagnosis of Cardiac Amyloidosis
O B J E C T I V E S This study sought to explore the potential role of noncontrast myocardial T1 mapping
for detection of cardiac involvement in patients with primary amyloid light-chain (AL) amyloidosis.
B A C KG ROUND Cardiac involvement carries a poor prognosis in systemic AL amyloidosis. Late
adolinium enhancement (LGE) cardiac magnetic resonance (CMR) is useful for the detection of cardiac
myloid, but characteristic LGE patterns do not always occur or they appear late in the disease.
oncontrast characterization of amyloidotic myocardium with T1 mapping may improve disease
etection. Furthermore, quantitative assessment of myocardial amyloid load would be of great value.
METHOD S Fifty-three AL amyloidosis patients (14 with no cardiac involvement, 11 with possible
nvolvement, and 28 with deﬁnite cardiac involvement based on standard biomarker and echocardio-
raphic criteria) underwent CMR (1.5-T) including noncontrast T1 mapping (shortened modiﬁed
ook-locker inversion recovery [ShMOLLI] sequence) and LGE imaging. These were compared with 36
ealthy volunteers and 17 patients with aortic stenosis and a comparable degree of left ventricular
ypertrophy as the cardiac amyloid patients.
R E S U L T S Myocardial T1 was signiﬁcantly elevated in cardiac AL amyloidosis patients (1,140  61 ms)
ompared to normal subjects (958 20 ms, p 0.001) and patients with aortic stenosis (979 51 ms, p
.001). Myocardial T1 was increased in AL amyloid even when cardiac involvement was uncertain (1,048 
8 ms) or thought absent (1,009  31 ms). A noncontrast myocardial T1 cutoff of 1,020 ms yielded 92%
ccuracy for identifying amyloid patients with possible or deﬁnite cardiac involvement. In the AL amyloidosis
ohort, there were signiﬁcant correlations between myocardial T1 time and indices of systolic and diastolic
ysfunction.
CONC L U S I O N S Noncontrast T1 mapping has high diagnostic accuracy for detecting cardiac AL
myloidosis, correlates well with markers of systolic and diastolic dysfunction, and is potentially more
ensitive for detecting early disease than LGE imaging. Elevated myocardial T1 may represent a direct marker
f cardiac amyloid load. Further studies are needed to assess the prognostic signiﬁcance of T1
levation. (J Am Coll Cardiol Img 2013;6:488–97) © 2013 by the American College of Cardiology Foundation
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490myloidosis is a group of diseases in which
proteins misfold to form insoluble fibrils that
accumulate in the extracellular space and
disrupt the structure and function of
any tissues and organs (1). Cardiac involvement is
ommon and is a principal cause of morbidity and
ortality particularly in primary amyloid light-
hain (AL) amyloidosis (1–3). Although endo-
yocardial biopsy is the gold standard for dem-
nstrating cardiac amyloid deposits, it is not
outinely performed because it is invasive and, in
ractice, much reliance has been placed on the
ollective diagnostic value of clinical features,
lectrocardiography (ECG) and echocardiogra-
hy, supported by the presence of amyloid in
xtracardiac sites (1).
See page 498
Cardiac magnetic resonance (CMR)
with late gadolinium enhancement (LGE)
provides unique information on myocar-
dial tissue characterization in patients with
cardiac amyloidosis (4–8). A characteris-
tic appearance of global, subendocardial
LGE is the hallmark for identifying car-
diac involvement, which substantially aids
the noninvasive diagnosis of cardiac amy-
loid, and correlates with prognosis (4,6).
However, the LGE technique has limita-
tions in evaluating patients with suspected
cardiac amyloidosis, many of whom have
significant renal impairment making ad-
ministration of a gadolinium-based con-
trast problematic. Furthermore, the pat-
tern of LGE may be atypical and patchy, even in
patients with life-threatening disease (1,4,7).
Therefore, a reproducible, noncontrast CMR tech-
nique that could provide accurate identification of
cardiac amyloidosis and, ideally, quantitative assess-
ment of myocardial amyloid load would be of great
value.
Measurement of myocardial T1 relaxation times
using noncontrast magnetic resonance T1 mapping
has the potential to be useful in the detection of
interstitial expansion due to myocardial edema and
fibrosis (9–12). In patients with systemic AL am-
yloidosis, alterations of T1 times in the liver, spleen,
and fat have been described using low-field mag-
netic resonance imaging (13). Therefore, we hy-
pothesized that noncontrast T1 mapping would
provide diagnostic information in patients with
ified
rysuspected cardiac AL amyloidosis.M E T H O D S
Study population. Fifty-three patients with systemic
(primary) AL amyloidosis and no contraindications
for CMR were recruited from the United Kingdom
National Amyloidosis Centre (Royal Free Hospital,
London, UK) between 2010 and 2011. All patients
had histological confirmation of systemic AL amy-
loidosis by Congo red and immunohistochemical
staining, which was obtained through specimens of
kidney (n  15), bone marrow (n  8), soft tissues
(n  8), fat (n  5), rectum (n  5), endomyocar-
dium (n  4), liver (n  2), lymph node (n  2),
upper gastrointestinal tract (n  1), lung (n  1),
bladder (n  1), and peritoneum (n  1). Partici-
pants were required to have glomerular filtration
rate 30 ml/min since LGE was performed.
On the basis of a combination of clinical and
echocardiographic features, amyloid patients were
categorized as having no (n  14), possible (n 
11), and definite (n 28) cardiac involvement. The
categorization into definite or no cardiac involve-
ment was based on international consensus criteria
(14). An additional category of possible involve-
ment was created for patients with cardiac abnor-
malities in whom there were confounding features.
The categorization was defined as follows: definite
cardiac involvement includes either of the follow-
ing: 1) left ventricular (LV) wall thickness of 12
mm in the absence of any other known cause; or 2)
right ventricular (RV) free wall thickening coexist-
ing with LV thickening in the absence of systemic
or pulmonary hypertension. Possible cardiac in-
volvement includes any of the following: 1) LV wall
thickening in the presence of hypertension; 2) RV
thickening in the presence of pulmonary hyperten-
sion; and 3) normal wall thickness with diastolic
dysfunction and raised serum biomarkers. No sus-
pected involvement is defined as normal wall thick-
ness with normal serum biomarkers.
In addition, 17 patients with moderate to severe
aortic stenosis according to established criteria (15),
such as peak aortic valve gradient 36 mm Hg or
valve area 1.5 cm2, were recruited from cardiology
outpatient clinics at the John Radcliffe Hospital in
Oxford, UK. Thirty-six normal volunteers were also
recruited. All healthy controls had no history or
symptoms of cardiovascular disease and no risk factors
(diabetes mellitus, hypertension). All patients and
healthy controls underwent 12-lead ECG. The study
was approved by the institutional ethics committees,A B B R E V I A T I O N S
A N D A C R O N YM S
AL amyloid light-chain
CMR cardiac magnetic
resonance
ECG electrocardiography
LGE late gadolinium
enhancement
LV left ventricular
ROC receiver-operating
characteristic
RV right ventricular
ShMOLLI shortenedmodand all patients and normal volunteers gave written
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491informed consent. Table 1 shows the baseline charac-
eristics of patients and controls.
CMR protocol. All subjects underwent CMR with a
1.5-T clinical scanner (Avanto, Siemens Healthcare,
Erlangen, Germany). Images were acquired with the
patient supine, using anterior and posterior phased-
array surface coils. For cine CMR, from standard pilot
images, short-axis cine images covering the entire left
ventricle were acquired using a retrospectively ECG-
gated balance steady-state free precession sequence.
For T1 mapping, a midventricular short-axis and a
4-chamber long-axis plane were acquired using the
shortened modified look-locker inversion recovery
(ShMOLLI) sequence, as previously described (16).
Briefly, T1-maps were based on 7 images with specific
TI of 100 ms to 5,000 ms, collected using steady-state
free-precession readouts in a single breath-hold, typ-
ically as follows: repetition time/echo time 201.32/
1.07 ms, flip angle 35°, matrix 192  144, 107
phase-encoding steps, interpolated voxel size 0.9 
0.9 8 mm, cardiac delay time TD 500 ms; and 206
ms acquisition time for single image. For LGE CMR,
a bolus of 0.1 mmol/kg of gadolinium-based contrast
(gadoterate meglumine [Dotarem, Guerbet SA, Paris,
France]) followed by a 10-ml saline flush was admin-
istered. After a 5-min delay, ECG-gated images were
acquired in 3 long-axis and a stack of short-axis slices
identical to those of cine images using a breath-hold
gradient recalled echo phase-sensitive or magnitude
only inversion recovery sequence (17).
Echocardiography. Patients with systemic AL amy-
Table 1. Baseline Characteristics of the Cohort
Normal
(n  36)
Amyloid, No Cardiac
(n  14)
Age, yrs 59 4 58 12
Male/female 22/14 8/6
BSA, m2 1.9 0.2 2.0 0.3
NYHA functional class III — 0
eGFR, ml/min/1.73 m2 NA 85 10
Hemoglobin, g/dl NA 13 1
LVEDV index, ml/m2 77 13* 59 11†‡
LVESV index, ml/m2 20 5 16 5*‡
LVEF, % 74 5* 73 6*
LV mass index, g/m2 58 11*‡ 69 20*‡
ShMOLLI T1, ms 958 20* 1,009 31*†
E/A ratio NA 0.88 0.15*
E/E’ ratio NA 7.6 2.3*
E deceleration time, ms NA 204 42
Values are mean  SD or n. *Indicates p  0.01 versus amyloid with deﬁnite c
A  peak late transmitral diastolic velocity; BSA  body surface area; E  p
estimated glomerular ﬁltration rate; LV  left ventricular; LVEDV  left ventri
ventricular end-systolic volume; NA  not applicable; NYHA  New York Hearoidosis and aortic stenosis underwent a compre-ensive echocardiographic study using standard
echniques. Diastolic function assessments were
erformed using the average of at least 3 consecu-
ive beats for each of the following measurements:
eak early (E) and late (A) transmitral diastolic
elocity, E/A ratio, E-wave deceleration time, mi-
ral annular early (E’) velocity, and E/E’ ratio.
CMR image analysis. All CMR images and maps
were analyzed offline. Quantification of LV vol-
umes, ejection fraction, and mass was performed as
previously described using Argus software (Version
2002B, Siemens Medical Solutions) (18). For aortic
stenosis patients, aortic valve area was determined
by direct valve planimetry. For T1 measurements,
the midventricular short-axis and the 4-chamber
ShMOLLI image were manually contoured to out-
line the endocardium and epicardium, and the
average T1 value over all available images was
calculated using in-house software MC-ROI (myo-
cardial regions of interest [programmed by S.K.P.],
Interactive Data Language-IDL Version 6.1, ITT
Exelis, McLean, Virginia), as previously described
(16). The LGE images were visually analyzed for
the presence or absence of enhancement from a
reader blinded to T1 mapping results. The presence
of LGE was classified as: 1) patchy; 2) circumfer-
ential in the subendocardium; 3) diffuse circumfer-
ential involving the subendocardium and extending
to the epicardial layer; and 4) abnormal contrast
handling on T1 scout with no discernible LGE,
defined as myocardium nulling before blood on a
Amyloid,
ssible Cardiac
(n  11)
Amyloid,
Deﬁnite Cardiac
(n  28)
Aortic Stenosis
(n  17) p Value
65 10 63 10 63 5 0.07
7/4 20/8 12/5 0.85
2.0 0.2 1.9 0.3 2.0 0.1 0.42
1 2 0 —
74 32 77 20 NA 0.42
13 2 13 2 NA 0.95
58 9†‡ 65 11†‡ 77 10* 0.001
13 5*†‡ 25 8 23 9 0.001
77 6* 62 12†‡ 71 9* 0.001
77 20*‡ 118 32† 104 18† 0.001
1,048 48*†‡ 1,140 61†‡ 979 51* 0.001
0.97 0.38* 1.72 0.81 NA 0.001
14.2 4.5 15.4 6.4 NA 0.001
231 66* 174 62 NA 0.03
c involvement; †p  0.01 versus normal; ‡p  0.01 versus aortic stenosis.
early transmitral diastolic velocity; E’  mitral annular early velocity; eGFR 
end-diastolic volume; LVEF  left ventricular ejection fraction; LVESV  left
ociation; ShMOLLI  shortened modiﬁed look-locker inversion recovery.Po
ardia
eak
cular5-min post-contrast TI scout.
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492Statistical analysis. Statistical analysis was per-
ormed using IBM SPSS Statistics Version 19
IBM, Somers, New York) and MedCalc Version
2 (MedCalc Software, Mariakerke, Belgium). All
ontinuous variables were normally distributed
Kolmogorov-Smirnov test) and are presented as
ean  SD. Comparisons between groups were
erformed by 1-way analysis of variance with post-
oc Bonferroni correction. The chi-square test or
isher exact test was used to compare discrete data
s appropriate. Receiver-operating characteristic
ROC) curve analysis was performed to define a T1
elaxation time cutoff value that identifies cardiac
nvolvement with the greatest sum of sensitivity and
pecificity. Correlation between continuous vari-
bles was assessed using Pearson (r) test. Statistical
ignificance was defined as p  0.05.
R E S U L T S
Subject characteristics are described in Table 1.
There were no differences in age, sex, and body
surface area among the 5 groups of subjects. Sub-
jects with definite cardiac amyloid had significantly
increased LV mass index (p  0.001) and smaller
P = 0.003
P < 0.0
P < 0.001
T1
 T
im
e 
(m
s)
1300
1200
1100
1000
900
Normals Amyloid,
No Cardiac
Involvement
Figure 1. Myocardial T1 in Normal, Amyloid, and Aortic Stenosi
Mean noncontrast shortened modiﬁed look-locker inversion recove
1 SD. Other between-groups comparisons: amyloid without cardiac
without cardiac involvement versus deﬁnite cardiac amyloid, p  0
0.606; possible cardiac amyloid versus deﬁnite cardiac amyloid, p 
deﬁnite cardiac amyloid versus aortic stenosis, p  0.001.V end-diastolic volume (p  0.001) compared toealthy controls. The degree of LV hypertrophy
as similar in patients with definite cardiac involve-
ent and aortic stenosis (p  0.11). Ejection
raction was slightly lower in patients with definite
ardiac involvement compared to the other groups
p  0.01 for all comparisons), although values
emained within normal limits. Peak systolic aortic
elocity in patients with aortic stenosis was 3.8 
.5 m/s, and the mean valve area was 1.1 0.2 cm2.
t the time of the CMR scan, only 1 patient with
ossible cardiac amyloidosis and 2 patients with
efinite cardiac amyloidosis were in New York
eart Association functional class III. All other
atients were in New York Heart Association
unctional class I or II. There were no differences in
enal function and hemoglobin among the 3 groups
f systemic AL amyloidosis patients.
T1 relaxation times in amyloidosis, healthy controls,
and aortic stenosis. There were significant differences
n noncontrast myocardial ShMOLLI T1 relaxation
imes among the 5 subject groups (Fig. 1). Patients
ith definite cardiac AL amyloidosis had signifi-
antly elevated myocardial T1 times (1,140  61 ms)
compared to normal controls (958  20 ms, p 
P = 0.3
myloid,
ossible
ardiac
lvement
Amyloid,
Definite
Cardiac
Involvement
Aortic
Stenosis
hMOLLI) T1 values in 5 groups of patients. Error bars indicate 
lvement versus possible cardiac amyloid, p  0.265; amyloid
; amyloid without cardiac involvement versus aortic stenosis, p 
01; possible cardiac amyloid versus aortic stenosis, p  0.001; and01
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493hypertrophy (979 51 ms, p 0.001). Myocardial
T1 times were slightly increased in patients with
aortic stenosis (979  51 ms) compared to healthy
controls (958  20 ms), but this small difference
as not significant after Bonferroni correction for
ultiple comparisons. In amyloid, myocardial T1
imes showed a stepwise elevation as the probability
or cardiac involvement increased (1,009  31 ms
n AL amyloid without cardiac involvement vs.
,048  48 ms in AL amyloid with possible cardiac
nvolvement vs. 1,140  61 ms in definite cardiac
myloid, p for trend  0.001). Amyloid patients
ith no cardiac involvement had increased T1
alues (1,009  31 ms) compared to controls (958 
20 ms, p  0.003) but not compared to aortic
stenosis patients (979  51 ms, p  0.606) or
ossible cardiac amyloid patients (1,048  48 ms,
 0.265) (Fig. 1).
Noncontrast myocardial T1-mapping and diagnosis of
cardiac amyloid. To identify a T1 threshold that
defines cardiac involvement, healthy controls, pa-
tients with aortic stenosis and AL amyloid patients
with no cardiac involvement were grouped together
as negative cases. Amyloid patients with possible or
definite cardiac involvement formed the positive
cases group. The ROC analysis (Fig. 2) showed
Se
ns
iti
vi
ty
100
80
60
40
20
0
100-Specificity
Non-contrast ShMOLLI T1
0 20 40 60
AUC 0.97±0.01
P < 0.001
Sensitivity  92%
Specificity  91%
80 100
Figure 2. ROC Curve for T1 Threshold
Receiver-operating characteristic (ROC) curve to detect the opti-
mal T1 threshold to detect primary amyloid light-chain (AL)
amyloid patients with possible or deﬁnite cardiac involvement
as opposed to patients with no cardiac amyloid (normal, aortic
stenosis, and patients with AL amyloidosis but no cardiac
involvement based on clinical criteria). AUC  area under the
curve; other abbreviation as in Figure 1.that a noncontrast ShMOLLI myocardial T1 cut-off value of 1,020 ms yielded an area under the
ROC curve of 0.97  0.01 (p  0.0001), with 92%
diagnostic accuracy for identifying cardiac involve-
ment. Based on this cutoff, 0 of 28 patients with
definite and 3 of 11 patients with possible cardiac
amyloid would have been misclassified (false nega-
tives, sensitivity 92%). False positive results oc-
curred in 0 of 36 normals, 3 of 17 aortic stenosis
patients, and 3 of 14 amyloid patients with no
cardiac involvement (specificity 91%).
LGE ﬁndings and T1 in cardiac amyloid. The frequency
of LGE or abnormal contrast handling increased from
the no, possible, and definite cardiac involvement with
rates of 0%, 54%, and 96%, respectively. The possible
cardiac involvement group (n  11) comprised 5
patients with no LGE, 4 with LGE (3 with typical
circumferential subendocardial LGE, 1 with patchy
LGE), and 2 with abnormal contrast handling. The
definite cardiac involvement group (n 28) contained
1 patient with no LGE, 26 with LGE (9 with typical
circumferential subendocardial LGE, 6 with patchy
LGE, 11 with extensive LGE), and 1 with abnormal
contrast handling. Increased T1 times (above the
threshold of 1,020 ms) were present in all patients
with patchy or extensive LGE, 2 of 3 patients with
abnormal contrast handling on T1 scout, and 4 of 6
patients with possible or definite cardiac involvement
but no discernible LGE. Only 6 of 19 (32%) aortic
stenosis patients showed mild patchy midwall en-
hancement in the lateral wall. None of the normal
controls had LGE. Representative examples of the
CMR scans are shown in Figure 3.
T1 and myocardial function in cardiac amyloid. There
were significant correlations between noncontrast T1
relaxation times and indices of systolic and diastolic
function in the AL amyloidosis cohort. As T1 relax-
ation times increased, LV ejection fraction decreased
(r0.57, p 0.001) and LV mass index increased
r  0.58, p  0.001), suggesting that the changes in
yocardial T1 reflect to some extent the severity of
ardiac involvement (Fig. 4). In addition, T1 times
ncreased significantly as diastolic function worsened
s shown by a positive correlation between T1 times
nd E/E’ ratio (r  0.45, p  0.001) and a negative
orrelation between T1 times and E deceleration time
r  0.44, p  0.002).
D I S C U S S I O N
The major finding of this study is that patients with
systemic AL amyloidosis show markedly increased
noncontrast T1 relaxation times in the myocar-
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494dium. The T1 times are also increased in many
patients in whom currently used clinical investiga-
tions suggest cardiac involvement is uncertain or
absent. Among amyloid patients with overt car-
diac involvement, the T1 increases are more
pronounced than in patients with aortic stenosis
and a similar degree of ventricular wall thicken-
ing. Furthermore, noncontrast T1 relaxation
times correlate well with markers of systolic and
diastolic dysfunction, indicating that the eleva-
tion in myocardial T1 likely reflects the severity
of cardiac involvement. Thus, T1 mapping may
have potential as a valuable method for diagnos-
ing and quantifying cardiac involvement in sys-
temic AL amyloidosis.
Cardiac involvement (as assessed by current con-
ventional methods) is associated with very poor
prognosis in patients with AL amyloidosis, with a
median survival of 8 months compared to about 4
years among patients in whom the heart is spared
(19 –22). Its presence increasingly informs the
choice and intensity of chemotherapy with the
Figure 3. Characteristic Examples From CMR Scans
Cardiac magnetic resonance (CMR) end-diastolic frame from cine (le
olinium enhancement (LGE) images (right panel) in normal volunte
markedly elevated myocardial T1 time in the cardiac amyloid patien
normal control (955 ms) and the patient with aortic stenosis and le
abbreviations as in Figures 1 and 2.availability of various novel agents, some of whichhave cardiac toxicities (1,23). The gold standard
for diagnosis of cardiac involvement is cardiac
biopsy but sampling error prevents quantification
and can give rise to false negative results. Abnor-
malities of ECG such as low QRS voltages in
limb leads (0.5 mV) and poor R-wave progres-
sion in chest leads occur in as many as two-thirds
of cardiac AL amyloid patients (20,24). Echocar-
diography may demonstrate wall thickening, poor
longitudinal function, biatrial dilation, and early
diastolic and late systolic dysfunction (25,26), but
only in the advanced stage do these features
become discriminatory over other diseases such as
hypertensive heart. Biomarkers, particularly
N-terminal pro-B-type natriuretic peptide, and
high-sensitivity cardiac troponins are useful for
prognosis (19) and elevate early but nonspecifi-
cally. Radiolabeled serum amyloid P component
is unable to image amyloid in the motile myocar-
dium, and technetium-99m 3,3-diphosphono-1,
2-propanodicarboxylic acid (99mTc-DPD) scin-
tigraphy is frequently negative in cardiac AL
anel), ShMOLLI noncontrast T1 map (middle panel), and late gad-
ortic stenosis patient, and cardiac amyloid patient. Note the
,170 ms, into the red range of the color scale) compared to the
ntricular hypertrophy (998 ms). ED  end diastolic; otherft p
er, a
t (1
ft veamyloidosis (27,28).
1.
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495CMR provides additive information in cardiac
amyloid through myocardial tissue characterization
with contrast. The appearance of global, subendo-
cardial LGE and associated dark blood-pool is
characteristic and correlates with prognosis (4–8).
Other LGE patterns may exist, and LGE may
occur even without overt hypertrophy. However,
LGE patterns may be nonspecific or only occur in
later disease and require contrast, which may be
contraindicated in patients with renal failure, com-
mon with amyloid (29).
With the degree of myocardial infiltration pres-
ent in amyloid, noncontrast T1-mapping has the
potential to detect and also quantify cardiac in-
volvement and could become a clinically useful
diagnostic test. Furthermore, the lack of need for
contrast and the quantitative nature of T1 mapping
are particularly appealing for assessing prognosis
and the effects of treatment on amyloidosis patients.
Changes in T1 times had previously been demon-
strated in the liver, spleen, and fat in amyloidosis
using low-field magnetic resonance imaging (13),
and early results supported myocardial changes
(30–32). Here, we build on these results using the
more advanced shortened breath-hold T1 mapping
technique, incorporating a single color T1 map (16)
in a large cohort with robust controls, and dem-
onstrate functional consequences and early dis-
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Figure 4. Correlations Between Myocardial T1 and LV Indices in
Scatterplots showing a positive correlation between ShMOLLI T1 va
correlation with LV ejection fraction (EF) (right panel). Error curves
amyloid with no cardiac involvement; green dots indicate amyloid
with deﬁnite cardiac involvement. Other abbreviations as in Figureease detection. Although there are technical dif-ferences between CMR sequences used to
measure T1 relaxation times, our results are in
agreement with previous work from Hosch et al.
(30) who found a 19% increase in T1 times in
cardiac amyloid patients compared to normal
controls. Furthermore, we found that the T1
elevation in amyloid with definite cardiac in-
volvement and wall thickening was higher than in
measurements in aortic stenosis with similar hy-
pertrophy, providing specificity for the technique.
The higher T1 values likely reflect either the
increase in the proportion of amyloid compared
to fibrosis for similar wall thickness increase, or
greater T1 prolongation by amyloid compared to
myocardial fibrosis. Our T1 results in patients
with moderate-severe aortic stenosis should be
interpreted with caution as it is likely that pa-
tients with more severe aortic stenosis and more
fibrosis will exhibit a greater degree of T1 eleva-
tion. Further work will be needed to clarify this.
Measurement of myocardial T1 times using
ShMOLLI has shown very good accuracy for the
detection of cardiac involvement in AL amyloidosis
and correlate well with the extent of systolic and
diastolic dysfunction. It is tempting to speculate
that noncontrast T1 mapping is more sensitive than
LGE-CMR for the detection of cardiac involve-
ment as all amyloid patients with nontypical patchy
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496more, T1 values in the AL amyloid without cardiac
involvement group were significantly increased
compared to normal controls and patients with
aortic stenosis, indicating that at least some of these
patients may be at early stages of cardiac involve-
ment when clinical, echocardiographic, and LGE
characteristics fail to demonstrate specific changes.
Elevated myocardial T1 times likely represent a
direct marker of cardiac amyloid load and are
potentially more sensitive to early changes than
LGE imaging. These preliminary findings need
further confirmation in large scale studies that will
assess not only the diagnostic and prognostic value
of noncontrast T1 mapping but also the effect of
therapy on T1 values.
Study limitations. Study patients had histologically
roven amyloid but had not systematically under-
one endomyocardial biopsy, as is standard clinical
ractice in the UK National Amyloidosis Center.
herefore, no histological correlation with T1 val-
es is available. This study explored noncontrast T1
apping (applicable to even patients with renal
ailure) rather than extracellular volume quantifica-
ion with contrast. Post-contrast T1 mapping and
xtracellular volume imaging have been shown to be
seful in detecting diffuse interstitial fibrosis (33–
5) and have recently provided interesting insights
nto cardiac amyloid (36). Two-dimensional T1
apping is also subject to sampling error because it
s not a 3-dimensional acquisition and endocardial
1 values may be affected by partial voluming of111:186–93. 14:15.ned (infiltrated) myocardium in cardiac amyloid
elp to minimize these. A more comprehensive
over of the left ventricle will likely facilitate mon-
toring of disease progression and treatment.
otion-corrected MOLLI can also help reduce
dge errors further (37). The prognostic signifi-
ance of T1 elevation also remains to be evaluated.
he study only explores AL amyloid, not transthy-
etin amyloid, and the translation of our findings to
ifferent amyloid types is unknown. Finally, as T1
apping is still an evolving field, it is unclear
hether patients with other infiltrative cardiomy-
pathies or hypertrophic cardiomyopathy and ex-
ensive fibrosis would exhibit similar degrees of
oncontrast T1 times prolongation. Ongoing studies
re expected to answer this question and clarify the
pecificity of our findings.
C O N C L U S I O N S
Noncontrast T1 mapping has high diagnostic ac-
curacy for the detection of cardiac AL amyloidosis
and correlates well with markers of systolic and
diastolic dysfunction. It may be more sensitive than
LGE imaging for identifying early cardiac disease,
but further studies are needed to assess this and the
prognostic significance of T1 elevation.
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